About En Carta
Located in the heart of Paris, born out of a passion for synthetic biology
and a dream to break the barriers in equal healthcare access,
En Carta employs its groundbreaking technology in a powerful and versatile diagnostics platform.
We develop accurate, accessible, and affordable molecular diagnostics to be used by anyone, anywhere.
We offer our customers the full power of our molecular diagnostics
platform – ready-to-use tests against validated targets,
as well as in-house development of new tools
against virtually any DNA or RNA target.
We believe that enabling everyone to easily detect and identify infections in the comfort of their own home will transform the patients’ journeys.
We are a diagnostic solution for the future.
Our diagnostics are used for medical applications.
We take this responsibility seriously and do not compromise on quality.
Synthetic biology is a new and exciting field of science.
The possibilities are endless, but we need a compass to guide our paths of discovery.
We believe that following the best Environmental, Social and Governance (ESG) practices today will make En Carta a sustainable company.
THEY TALK ABOUT US!
En Carta co-Founders receive prestigious DARPA grant
Our co-founders Alex Green and Keith Pardee have been awarded a prestigious DARPA collaborative $17.7 million agreement for project SPITFIRE.
50 Partners Annual Conference
Our CEO Guillaume Horreard showcased En Carta Diagnostics at the Annual Conference of 50 Partners
En Carta graduated from the incubator Creative Destruction Lab.
ASU Skysong Innovation Startup Challenge
Our technology convinced the jury who awarded En Carta a $25,000 USD prize
En Carta Diagnostics was selected to be part of the innovation accelerator Wilco for the S2022 biotech and smart pharma cohort.